MetLife Investment Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,633
| Closed | -$267K | – | 2890 |
|
|
2026
Q1 | $267K | Sell |
6,633
-329
| -5% | -$7.09K | ﹤0.01% | 2075 |
|
|
2025
Q4 | $175K | Buy |
6,962
+60
| +0.9% | +$1.41K | ﹤0.01% | 2339 |
|
|
2025
Q3 | $156K | Buy |
6,902
+199
| +3% | +$4.64K | ﹤0.01% | 2450 |
|
|
2025
Q2 | $116K | Buy |
6,703
+117
| +2% | +$2.17K | ﹤0.01% | 2462 |
|
|
2025
Q1 | $144K | Buy |
6,586
+150
| +2% | +$4.14K | ﹤0.01% | 2368 |
|
|
2024
Q4 | $205K | Sell |
6,436
-146
| -2% | -$4.39K | ﹤0.01% | 2289 |
|
|
2024
Q3 | $190K | Sell |
6,582
-129
| -2% | -$4.78K | ﹤0.01% | 2316 |
|
|
2024
Q2 | $257K | Buy |
6,711
+565
| +9% | +$25.6K | ﹤0.01% | 2089 |
|
|
2024
Q1 | $361K | Buy |
6,146
+19
| +0.3% | +$1.21K | ﹤0.01% | 1853 |
|
|
2023
Q4 | $367K | Sell |
6,127
-1
| -0% | -$51 | ﹤0.01% | 1871 |
|
|
2023
Q3 | $233K | Buy |
6,128
+2
| +0% | +$88 | ﹤0.01% | 2116 |
|
|
2023
Q2 | $558K | Sell |
6,126
-42,949
| -88% | -$3.71M | ﹤0.01% | 1625 |
|
|
2023
Q1 | $3.24M | Sell |
49,075
-590
| -1% | -$34K | 0.02% | 701 |
|
|
2022
Q4 | $2.57M | Hold |
49,665
| – | – | 0.02% | 792 |
|
|
2022
Q3 | $3.39M | Buy |
49,665
+2,428
| +5% | +$144K | 0.03% | 622 |
|
|
2022
Q2 | $2.14M | Buy |
47,237
+5,944
| +14% | +$271K | 0.02% | 879 |
|
|
2022
Q1 | $2.1M | Buy |
41,293
+16,567
| +67% | +$731K | 0.01% | 972 |
|
|
2021
Q4 | $1.17M | Buy |
24,726
+527
| +2% | +$20.7K | 0.01% | 1067 |
|
|
2021
Q3 | $798K | Hold |
24,199
| – | – | 0.01% | 1251 |
|
|
2021
Q2 | $1.53M | Hold |
24,199
| – | – | 0.01% | 973 |
|
|
2021
Q1 | $1.04M | Hold |
24,199
| – | – | 0.01% | 1139 |
|
|
2020
Q4 | $1.38M | Sell |
24,199
-2,552
| -10% | -$108K | 0.01% | 990 |
|
|
2020
Q3 | $807K | Hold |
26,751
| – | – | 0.01% | 1137 |
|
|
2020
Q2 | $874K | Buy |
26,751
+1,387
| +5% | +$44.5K | 0.01% | 1088 |
|
|
2020
Q1 | $680K | Buy |
25,364
+3,069
| +14% | +$109K | 0.01% | 1062 |
|
|
2019
Q4 | $683K | Hold |
22,295
| – | – | 0.01% | 1288 |
|
|
2019
Q3 | $537K | Hold |
22,295
| – | – | 0.01% | 1382 |
|
|
2019
Q2 | $565K | Buy |
22,295
+4,997
| +29% | +$102K | 0.01% | 1405 |
|
|
2019
Q1 | $337K | Hold |
17,298
| – | – | ﹤0.01% | 1687 |
|
|
2018
Q4 | $228K | Hold |
17,298
| – | – | ﹤0.01% | 1832 |
|
|
2018
Q3 | $308K | Buy |
+17,298
| New | +$320K | ﹤0.01% | 1846 |
|
|
2018
Q2 | – | Sell |
-5,716
| Closed | -$126K | – | 2167 |
|
|
2018
Q1 | $126K | Buy |
+5,716
| New | +$112K | ﹤0.01% | 2116 |
|
Other funds holding APLS
MetLife Investment Management's APLS Position: Q2 2026 in Review
MetLife Investment Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,633 shares — an estimated $267K sold.
MetLife Investment Management first reported a position in APLS in Q1 2018 and held it in 32 quarters. The position peaked at $3.39M in Q3 2022. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- MetLife Investment Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- MetLife Investment Management sold 6,633 Apellis Pharmaceuticals shares in Q2 2026, an estimated $267K.
- MetLife Investment Management first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 32 quarters.
- MetLife Investment Management's Apellis Pharmaceuticals position peaked at $3.39M in Q3 2022.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.